Eurobio Scientific SA
PAR:ALERS

Watchlist Manager
Eurobio Scientific SA Logo
Eurobio Scientific SA
PAR:ALERS
Watchlist
Price: 25.25 EUR -0.2% Market Closed
Market Cap: 258.8m EUR

EV/EBITDA
Enterprise Value to EBITDA

8.5
Current
5.8
Median
4.4
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
8.5
=
Enterprise Value
261.6m EUR
/
EBITDA
30.7m EUR
EBITDA Growth EV/EBITDA to Growth
FR
Eurobio Scientific SA
PAR:ALERS
Average EV/EBITDA: 14.6
8.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 980.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -567.8 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -661.6 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
8
2-Years Forward
EV/EBITDA
6.8
3-Years Forward
EV/EBITDA
N/A